PDCD1 and melanoma: Hypothesizing that similar mechanisms in a tumor microenvironment may attenuate anti-tumor immunity, we observed that expression of SIGLEC10, the human homolog of Siglecg, was associated with resistance to anti-PD1 therapy in human melanomas.